Romano Danesi
#150,841
Most Influential Person Now
Researcher
Romano Danesi's AcademicInfluence.com Rankings
Romano Danesicomputer-science Degrees
Computer Science
#7925
World Rank
#8341
Historical Rank
Machine Learning
#3101
World Rank
#3140
Historical Rank
Artificial Intelligence
#3403
World Rank
#3453
Historical Rank
Database
#4982
World Rank
#5176
Historical Rank
Download Badge
Computer Science
Romano Danesi's Degrees
- Masters Artificial Intelligence University of Milan
- Bachelors Computer Engineering University of Florence
Similar Degrees You Can Earn
Why Is Romano Danesi Influential?
(Suggest an Edit or Addition)Romano Danesi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. (2010) (439)
- Molecular basis of resistance to azole antifungals. (2002) (420)
- Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. (2006) (347)
- Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial (2019) (227)
- Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. (2003) (222)
- Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients (2008) (209)
- The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. (2017) (208)
- Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs (2002) (201)
- Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non–Small-Cell Lung Cancer Cells (2005) (186)
- Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer (2008) (184)
- Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer (2011) (178)
- The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors (2009) (170)
- Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. (2012) (162)
- Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells (2008) (157)
- EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis (2012) (156)
- PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC (2018) (155)
- Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. (2002) (149)
- The pharmacological bases of the antiangiogenic activity of paclitaxel (2013) (145)
- Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. (2019) (133)
- Cardiac toxicity of antineoplastic anthracyclines. (2003) (125)
- DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. (2013) (123)
- Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. (2011) (117)
- Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN‐38 (2004) (114)
- Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. (2001) (108)
- Clinical pharmacology of intravitreal anti-VEGF drugs (2018) (105)
- Synergistic Cytotoxicity and Pharmacogenetics of Gemcitabine and Pemetrexed Combination in Pancreatic Cancer Cell Lines (2004) (102)
- Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). (1997) (101)
- Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. (1999) (100)
- CYP2D6 polymorphisms and the impact on tamoxifen therapy. (2007) (99)
- Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib (2010) (99)
- Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. (2000) (97)
- Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib (2008) (95)
- Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. (1997) (95)
- The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects (2017) (95)
- Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells (2012) (92)
- Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer (2006) (92)
- Polycomb genes and cancer: time for clinical application? (2012) (90)
- Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer (2011) (89)
- BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer (2011) (89)
- Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer (2009) (88)
- EPMA position paper in cancer: current overview and future perspectives (2015) (86)
- Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. (1990) (86)
- Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. (2011) (85)
- Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38 (2004) (85)
- Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel (2008) (82)
- ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. (2011) (81)
- Effect of suramin on human prostate cancer cells in vitro. (1991) (79)
- Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. (1993) (78)
- Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA (2016) (78)
- The emerging role of histone lysine demethylases in prostate cancer (2012) (78)
- Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells (2005) (74)
- Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy. (2018) (73)
- Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer (2003) (72)
- An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. (1999) (71)
- Hematologic toxicity of immunosuppressive treatment. (2004) (70)
- Geranylgeraniol Overcomes the Block of Cell Proliferation by Lovastatin in C6 Glioma Cells (1998) (70)
- A pharmacokinetic‐based test to prevent severe 5‐fluorouracil toxicity (2006) (69)
- Cancer stem cell epigenetics and chemoresistance. (2009) (69)
- A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients (2008) (68)
- Antimicrobial peptides: therapeutic potential for the treatment of Candida infections (2002) (67)
- Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib (2010) (66)
- Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation (2011) (65)
- Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma (2005) (65)
- Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood Samples (2008) (65)
- Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers (2012) (64)
- Periodontal tissue disposition of azithromycin. (1997) (64)
- Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. (2015) (64)
- Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. (2001) (62)
- Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo (1999) (61)
- Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. (1995) (61)
- Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. (2002) (61)
- A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer (2008) (59)
- Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. (2003) (59)
- Pharmacogenetic determinants of anti-cancer drug activity and toxicity. (2001) (59)
- Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer (2017) (58)
- Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer (2006) (58)
- Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. (2007) (56)
- Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. (2011) (56)
- Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy (2019) (55)
- Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients (2019) (55)
- 5-Fluorouracil Pharmacokinetics Predicts Disease-free Survival in Patients Administered Adjuvant Chemotherapy for Colorectal Cancer (2008) (55)
- Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. (2011) (54)
- Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. (1991) (54)
- Suramin, a novel antitumor compound (1990) (53)
- Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment (2018) (53)
- ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. (2009) (53)
- Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients (2010) (52)
- Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper (2018) (52)
- Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer (2010) (52)
- Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study* (2001) (52)
- Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. (2004) (51)
- Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. (2017) (51)
- Pharmacological Issues of Linezolid (2010) (51)
- Measurement of the S alpha T segment as the most reliable electrocardiogram parameter for the assessment of adriamycin-induced cardiotoxicity in the rat. (1986) (51)
- CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. (2014) (50)
- Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. (2016) (50)
- CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. (2012) (50)
- A pilot study of suramin in the treatment of metastatic renal cell carcinoma (1991) (50)
- Specific labeling of isoprenylated proteins: application to study inhibitors of the post-translational farnesylation and geranylgeranylation. (1995) (49)
- Histone lysine demethylases in breast cancer. (2013) (49)
- In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients (2006) (49)
- An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. (2012) (48)
- Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients (2016) (48)
- The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. (2017) (48)
- In-vitro evidence of autocrine secretion of vascular endothelial growth factor by endothelial cells from human placental blood vessels. (2001) (47)
- Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. (2002) (47)
- The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies☆ (2021) (47)
- Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues. (2001) (47)
- ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview (2016) (46)
- Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. (1996) (46)
- The effects of the somatostatin analog octreotide on angiogenesis in vitro. (1996) (45)
- Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. (2009) (45)
- Teratogenesis and immunosuppressive treatment. (2004) (45)
- Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines (2009) (45)
- The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. (1998) (45)
- Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study (2020) (45)
- Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer (2015) (44)
- Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. (2013) (44)
- Radiomics and liquid biopsy in oncology: the holons of systems medicine (2018) (43)
- Pharmacokinetic Optimisation of Treatment Schedules for Anthracyclines and Paclitaxel in Patients with Cancer (1999) (43)
- Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. (2017) (43)
- Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. (1994) (43)
- VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide (2013) (43)
- Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. (1995) (42)
- Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK‐Positive NSCLC With Disease Progression During Crizotinib Treatment (2017) (42)
- Might adriamycinol contribute to adriamycin-induced cardiotoxicity? (1985) (41)
- Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients (2006) (41)
- Genetic variation: effect on prostate cancer. (2014) (40)
- Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. (2001) (40)
- Anthracycline cardiotoxicity: in vivo and in vitro effects on biochemical parameters and heart ultrastructure of the rat. (1991) (40)
- The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia (2014) (39)
- Clinical Pharmacokinetics of Antibacterials in Cerebrospinal Fluid (2013) (39)
- Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1. (2012) (38)
- Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. (2020) (38)
- Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma (2008) (37)
- Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. (2007) (35)
- Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. (2007) (35)
- Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. (2009) (35)
- Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile (2005) (35)
- Pharmacogenetics of anti-estrogen treatment of breast cancer. (2012) (34)
- Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumourcells (2000) (34)
- Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. (2011) (34)
- Macrolide antibiotics as antiinflammatory agents: Roxithromycin in an unexpected role (2005) (34)
- DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients (2019) (33)
- Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. (2011) (33)
- VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. (2013) (33)
- Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials. (2016) (33)
- First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study (2012) (33)
- Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? (2016) (32)
- Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non‐Small Cell Lung Cancer: The Role of Cancer Stem Cells (2018) (32)
- Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins. (1996) (32)
- From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. (2019) (32)
- Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration‐resistant prostate cancer patients (2014) (32)
- A Rapid High-Performance Liquid Chromatography Method to Measure Linezolid and Daptomycin Concentrations in Human Plasma (2010) (32)
- Suramin in combination with weekly epirubicin for patients with advanced hormone‐refractory prostate carcinoma (1999) (31)
- Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. (2000) (31)
- MCF-10A cells infected with the int-2 oncogene induce angiogenesis in the chick chorioallantoic membrane and in the rat mesentery. (1994) (31)
- Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer. (2016) (31)
- The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response (2018) (31)
- Increased susceptibility of ras‐transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion (1995) (30)
- EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan (2014) (30)
- Pharmacogenomics in non-small-cell lung cancer chemotherapy. (2009) (30)
- Real‐Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2V617F mutation in Philadelphia‐negative chronic myeloproliferative neoplasms (2015) (30)
- In vitro antiangiogenic activity of selective somatostatin subtype‐1 receptor agonists (2007) (30)
- Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. (2004) (30)
- The Tumor-Agnostic Treatment For Patients with Solid Tumors: a Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBIOC-SIF Italian Scientific Societies. (2021) (29)
- Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. (2012) (29)
- Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia (2015) (29)
- Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. (2013) (29)
- IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients (2017) (28)
- Implications of KRAS mutations in acquired resistance to treatment in NSCLC (2015) (28)
- METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION‐RESISTANT PROSTATE CANCER (2010) (28)
- An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. (2004) (28)
- Pharmacogenetics of neoplastic diseases: new trends. (2004) (28)
- Pharmacogenomics and cancer stem cells: a changing landscape? (2011) (27)
- Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. (2015) (27)
- Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide (2021) (27)
- Suppression of Fas Expression and Down-Regulation of Fas Ligand in Highly Aggressive Human Thyroid Carcinoma (2000) (27)
- An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw. (2012) (27)
- Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaks. (1996) (26)
- Improved Analysis of 5-Fluorouracil and 5,6-Dihydro-5-Fluorouracil by HPLC With Diode Array Detection for Determination of Cellular Dihydropyrimidine Dehydrogenase Activity and Pharmacokinetic Profiling (2005) (26)
- Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins (2017) (26)
- Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy. (2000) (26)
- Correlation of CDA , ERCC 1 , and XPD Polymorphisms with Response and Survival in Gemcitabine / Cisplatin ^ Treated Advanced Non ^ Small Cell Lung Cancer Patients (2008) (26)
- Relationship Between Plasma Concentrations of 5-Fluorouracil and 5-Fluoro-5,6-Dihydrouracil and Toxicity of 5-Fluorouracil Infusions in Cancer Patients (2002) (25)
- Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life. (2017) (25)
- Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients (2016) (25)
- Case Report of a Successful Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia and MRSA/Vancomycin-Resistant Enterococcus faecium Cholecystitis by Daptomycin (2011) (25)
- Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate (2009) (25)
- KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges. (2020) (25)
- The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review (2018) (25)
- Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. (2019) (25)
- Superoxide anion production by adriamycinol from cardiac sarcosomes and by mitochondrial NADH dehydrogenase. (1986) (24)
- Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications. (2013) (24)
- Augmentation of Clozapine with Aripiprazole in Severe Psychotic Bipolar and Schizoaffective Disorders: A Pilot Study (2010) (24)
- Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing. (2010) (24)
- Limited sampling model for the analysis of 5‐fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer (2002) (24)
- Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success (2019) (24)
- Understanding EGFR heterogeneity in lung cancer (2020) (24)
- A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC (2020) (24)
- Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. (2006) (24)
- Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. (1996) (24)
- Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells. (2011) (23)
- Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. (2009) (23)
- Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? (2010) (23)
- A Phase I and Pharmacokinetic Study of Irinotecan Given as a 7-Day Continuous Infusion in Metastatic Colorectal Cancer Patients Pretreated with 5-Fluorouracil or Raltitrexed (2004) (23)
- Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance (2021) (22)
- Effects of Octreotide on Angiogenesis (1996) (22)
- Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. (2019) (22)
- Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer. (2013) (22)
- Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)? (2020) (22)
- DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (2017) (22)
- Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells. (1997) (22)
- Linezolid in the central nervous system: Comparison between cerebrospinal fluid and plasma pharmacokinetics (2011) (22)
- Androgen receptor (AR) splice variant 7 and full‐length AR expression is associated with clinical outcome: a translational study in patients with castrate‐resistant prostate cancer (2019) (22)
- Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells (2001) (21)
- Refining sorafenib therapy: lessons from clinical practice. (2015) (21)
- Metronomic Chemotherapy for Metastatic Prostate Cancer (2010) (21)
- A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma (2013) (21)
- Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines (2009) (21)
- A Benefit-Risk Assessment of Basiliximab in Renal Transplantation (2004) (21)
- Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. (2011) (21)
- Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer (2010) (21)
- Infusions of Fluorouracil and Leucovorin: Effects of the Timing and Semi-Intermittency of Drug Delivery (1999) (20)
- Determinants of bone specific metastasis in prostate cancer. (2017) (20)
- Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis (2021) (20)
- Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. (2011) (20)
- Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. (2015) (19)
- Suramin in Combination with 5-Fluorouracil (5-FU) and Leucovorin (LV) in Metastatic Colorectal Cancer Patients Resistant to 5-FU+LV-Based Chemotherapy (1998) (19)
- Synergistic Cytotoxicity and Molecular Interaction on Drug Targets of Sorafenib and Gemcitabine in Human Pancreas Cancer Cells (2010) (19)
- Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. (2012) (19)
- Carbogen and nicotinamide combined with unconventional radiotherapy in glioblastoma multiforme: a new modality treatment. (1997) (19)
- Cardiovascular implantable electronic device endocarditis treated with daptomycin with or without transvenous removal. (2012) (19)
- The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. (2019) (19)
- Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients (2015) (19)
- CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo (2014) (18)
- Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature. (2013) (18)
- PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients. (2020) (18)
- Linezolid Cerebrospinal Fluid Concentration in Central Nervous System Infection (2007) (18)
- Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. (2021) (18)
- 3'-Deamino-3'-(2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762): a new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity. (1993) (18)
- Estrogen Receptor α and Aromatase Polymorphisms Affect Risk, Prognosis, and Therapeutic Outcome in Men with Castration-Resistant Prostate Cancer Treated with Docetaxel-Based Therapy (2011) (17)
- Phase II Study of High‐Dose Epirubicin in Untreated Patients with Small‐Cell Lung Cancer (1990) (17)
- Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia. (2000) (17)
- Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors (2015) (17)
- Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer (2020) (17)
- Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529 (2004) (17)
- Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients (2021) (17)
- EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. (2018) (17)
- Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. (2014) (17)
- Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine‐based chemotherapy. A phase II Study (1995) (17)
- Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions. (2010) (17)
- Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro. (2014) (17)
- Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant. (2016) (17)
- The rs2071559 AA VEGFR-2 Genotype Frequency Is Significantly Lower in Neovascular Age-Related Macular Degeneration Patients (2012) (16)
- Idarubicin and Idarubicinol Effects on Breast Cancer Multicellular Spheroids (2005) (16)
- Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer (2014) (16)
- Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro (2018) (16)
- Clinical study on the efficacy of clofoctol in the treatment of infectious respiratory diseases. (1985) (16)
- Clinical and experimental evidence of inhibition of testosterone production by suramin. (1996) (16)
- Differential affinities of AF-DX 116, atropine and pirenzepine for muscarinic receptors of guinea pig gastric fundus, atria and urinary bladder: might atropine distinguish among muscarinic receptor subtypes? (1990) (16)
- Superoxide anion production by doxorubicin analogs in heart sarcosomes and by mitochondrial NADH dehydrogenase. (1990) (16)
- Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors. (2020) (16)
- Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors. (2017) (15)
- Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy (2021) (15)
- In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma. (2006) (15)
- Effects of thymostimulin on chemotherapy-induced toxicity and long-term survival in small cell lung cancer patients. (1989) (15)
- Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. (2018) (15)
- Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report (2002) (15)
- Epileptogenesis and oncogenesis: An antineoplastic role for antiepileptic drugs in brain tumours? (2020) (15)
- Molecular targeted treatments for fungal infections: the role of drug combinations. (2003) (15)
- Precision Medicine in Lymphoma by Innovative Instrumental Platforms (2019) (15)
- Study of Apoptosis Induction and Deoxycytidine Kinase/Cytidine Deaminase Modulation in the Synergistic Interaction of a Novel Ceramide Analog and Gemcitabine in Pancreatic Cancer Cells (2010) (14)
- erbB in NSCLC as a molecular target: current evidences and future directions (2020) (14)
- Faithful markers of circulating cancer stem cells: is CD133 sufficient for validation in clinics? (2011) (14)
- In vitro studies on gemcitabine combinations with other antiblastics. (2006) (14)
- AR-V7 detection in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer (2016) (14)
- Doxorubicin cardiotoxicity is associated with alterations of plasma levels of atrial natriuretic factor (1992) (14)
- Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens (1999) (13)
- Roxithromycin penetration into gingiva and alveolar bone of odontoiatric patients. (1990) (13)
- Suicide Gene Therapy With the Yeast Fusion Gene Cytosine Deaminase/Uracil Phosphoribosyltransferase Is Not Enough for Pancreatic Cancer (2007) (13)
- Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines (2012) (13)
- The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer. (2000) (13)
- The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report (2019) (13)
- Ceramide analogues in apoptosis: a new strategy for anticancer drug development. (2003) (12)
- Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment (2017) (12)
- Pharmacogenetics and Proteomics of Anticancer Drugs in Non-Hodgkin's Lymphoma (2003) (12)
- High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). (2001) (12)
- Pharmacokinetic Optimisation of the Treatment of Cancer with High Dose Zidovudine (1998) (12)
- Cytofluorescence localization and disposition of doxorubicin and doxorubicinol in rat cardiac tissue. (1988) (12)
- A Common mdr1 Gene Polymorphism is Associated With Changes in Linezolid Clearance (2018) (11)
- Cholinergic toxic syndrome by the anticancer drug irinotecan: Acetylcholinesterase does not play a major role (2002) (11)
- Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer (2015) (11)
- Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia (2017) (11)
- A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. (2011) (11)
- Penetration of clofoctol into human lung. (1987) (11)
- Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation (2006) (11)
- Individualized dosing with axitinib: rationale and practical guidance. (2018) (11)
- The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia (2017) (11)
- Synergistic interaction between PPAR ligands and salbutamol on human bronchial smooth muscle cell proliferation (2013) (11)
- Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients (2015) (11)
- Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. (2014) (11)
- The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies (2022) (11)
- Exogenous doxorubicinol induces cardiotoxic effects in rats. (1987) (11)
- Time‐Dependent Pharmacokinetics of 5‐Fluorouracil and Association With Treatment Tolerability in the Adjuvant Setting of Colorectal Cancer (2012) (10)
- What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? - Considerations on pre-analytical aspects by the IFCC workgroup cfDNA. (2021) (10)
- Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. (2022) (10)
- Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas (2001) (10)
- Different recommendations for daptomycin dosing over time in patients with severe infections. (2014) (10)
- The penetration of roxithromycin into human skin. (1990) (10)
- Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors (2011) (10)
- Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck? (2016) (10)
- Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients. (2010) (10)
- Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. (2009) (10)
- Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell lines. (1995) (10)
- Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence (2019) (10)
- A new validated HPLC-UV method for therapeutic monitoring of daptomycin in comparison with reference mass spectrometry. (2020) (10)
- Correlation of cytidine deaminase (CDA), xeroderma pigmentosum group D (XPD) and excision repair cross-complementing 1 (ERCC1) genes single nucleotide polymorphisms (SNPS) with response and survival in gemcitabine/cisplatin treated advanced non-small-cell lung cancer (NSCLC) patients (2007) (9)
- Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel (2021) (9)
- Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. (2021) (9)
- Protective effects of fructose-1,6-diphosphate on acute and chronic doxorubicin cardiotoxicity in rats (2004) (9)
- Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: a preclinical study. (2001) (9)
- Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies (2022) (9)
- Cardiotoxicity and cytotoxicity of the anthracycline analog 4'-deoxy-4'-iodo-doxorubicin. (1991) (9)
- Promoting predictive, preventive and personalised medicine: European event of global importance (2011) (9)
- Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer (2021) (9)
- EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. (2012) (8)
- Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule (2017) (8)
- Pattern of growth factor, proto-oncogene and carcinoembryonic antigen gene expression in human colorectal carcinoma cell lines. (1992) (8)
- Ultrastructural and biochemical evidence of apoptosis induced by a novel inhibitor of protein geranylgeranylation in human MIA PaCa-2 pancreatic cancer cells. (1998) (8)
- Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications. (2016) (8)
- Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine. (2009) (8)
- Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo. (2017) (8)
- Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4′-amino-3′-hydroxy-doxorubicin (2004) (8)
- Involvement of basic fibroblast growth factor in suramin-induced inhibition of V79/AP4 fibroblast cell proliferation. (1993) (8)
- Effects of 4'-O-tetrahydropyranyl-doxorubicin on isolated perfused rat heart and cardiac mitochondrial cytochrome C oxidase activity. (1987) (8)
- Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms? (2008) (8)
- Optimizing Pemetrexed-Gemcitabine Combination in Patients with Advanced Non-small Cell Lung Cancer: A Pharmacogenetic Approach (2011) (8)
- Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment. (2018) (8)
- Administration Interval and Daptomycin Toxicity: A Case Report of Rhabdomyolysis (2010) (8)
- Characterization of the toxicity of distamycin derivatives on cancer cell lines and rat heart. (1992) (7)
- CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone (2020) (7)
- Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies. (1994) (7)
- Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy (2018) (7)
- Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients (2016) (7)
- Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. (2009) (7)
- High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine–epirubicin–paclitaxel in metastatic breast cancer: a dose finding study (2003) (7)
- Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015 (2016) (7)
- Serotonin syndrome and the T102-->C polymorphism of the 5-HT2A receptor: a case report. (2008) (7)
- Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients (2022) (7)
- Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer (2020) (7)
- Should CYP2D6 be genotyped when treating with tamoxifen? (2017) (7)
- EPMA-World Congress 2015 (2016) (7)
- Akt1 rs2498801 is related to survival in head and neck squamous cell cancer treated with radiotherapy. (2015) (7)
- Trapidil inhibits endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane and in the rat cornea. (1995) (7)
- Should CYP2D6 be genotyped when treating with tamoxifen? (2016) (7)
- General and cardiac toxicity of adriamycinol in rats. (1986) (7)
- 5-Fluorouracil Administered as a 48-Hour Chronomodulated Infusion in Combination with Leucovorin and Cisplatin: A Randomized Phase II Study in Metastatic Colorectal Cancer (2001) (7)
- Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase. (2017) (7)
- A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay. (1988) (6)
- Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. (2019) (6)
- Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers. (2020) (6)
- Efficacy and safety of basiliximab in kidney transplantation (2005) (6)
- Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment (2017) (6)
- Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy (2019) (6)
- The Role of Pharmacogenetics in Adjuvant Treatment of Non-small Cell Lung Cancer (2007) (6)
- Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. (2018) (6)
- The effect of osteogenic growth peptide (OGP) on proliferation and adhesion of HEMC-1 human endothelial cells. (2002) (6)
- Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring. (2019) (6)
- Pharmacokinetics and tolerance of nicotinamide combined with radiation therapy in patients with glioblastoma multiforme. (1994) (6)
- Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting. (2016) (6)
- The pharmacokinetic profile of clofoctol in rat plasma and tissues after oral and rectal administration. (1986) (6)
- Evaluation of the JT and corrected JT intervals as a new ECG method for monitoring doxorubicin cardiotoxicity in the dog. (1989) (5)
- Stable analogues of geranylgeranyl diphosphate possessing improved geranylgeranyl versus farnesyl protein transferase inhibitory selectivity. (2003) (5)
- Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time (2019) (5)
- Genetic interaction of P 2 X 7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients (2015) (5)
- Ceramide Analogues in Apoptosis: A New Strategy for Anticancer Drug Development (2003) (5)
- Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. (2004) (5)
- Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) mul (2021) (5)
- Phosphonomethylphosphorylmethyl(oxy)-analogues of geranylgeranyl diphosphate as stable and selective geranylgeranyl protein transferase inhibitors. (2004) (5)
- Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. (2020) (5)
- Imatinib administration in two patients with liver metastases from GIST and severe jaundice (2003) (5)
- Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor. (2003) (5)
- Synthesis of Stable Analogues of Geranylgeranyl Diphosphate Possessing a (Z,E,E)‐Geranylgeranyl Side Chain, Docking Analysis, and Biological Assays for Prenyl Protein Transferase Inhibition (2006) (5)
- The influence of amrinone on cardiac toxicity induced by adriamycin in rats. (1986) (4)
- The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences. (2022) (4)
- Clinical pharmacology differences among proteasome inhibitors: implications for their use in clinical practice. (2021) (4)
- Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer (2021) (4)
- Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position. (2018) (4)
- 5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice. (2005) (4)
- Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases. (2022) (4)
- [A selective antimuscarinic agent: pirenzepine. Review of its pharmacologic and clinical properties]. (1989) (4)
- Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer. (2021) (4)
- Suramin as an anticomplementary agent in xenotransplantation. (1992) (4)
- The effect of rhGM‐CSF on the proliferation of osteogenic sarcoma cells (1991) (4)
- A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study (2021) (4)
- Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data (2022) (4)
- Human skin disposition of cefpodoxime after oral administration of its proxetil ester. (1992) (4)
- Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin and 4'-deoxy-4'-iodo-doxorubicin. (1994) (4)
- DPYD and UGT 1 A 1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (2018) (4)
- An EZH 2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients (2012) (4)
- Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC: 2PD (2016) (3)
- Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment. (2019) (3)
- The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs (2022) (3)
- Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck? (2017) (3)
- Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers (2012) (3)
- Pharmacokinetics of irinotecan: Comparison of intravenous and intra-arterial administration in patients with liver metastases (2008) (3)
- TOP2A mRNA expression in HER2 negative breast cancer. (2009) (3)
- Depression of the immune responsiveness in mice treated with thioacetamide after antigen exposure. (1989) (3)
- An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. (2012) (3)
- Chemoembolization is effective as second-line therapy in patients with colorectal carcinoma metastatic to the liver. (2002) (3)
- Analysis of single nucleotide polymorphisms (SNPs) of cytidine deaminase (CDA) and xeroderma pigmentosum group D (XPD) genes for the prediction of clinical response to gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) patients. (2006) (3)
- Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study (2021) (3)
- Suramin therapy for malignant thymoma: a case report. (1994) (3)
- The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs (2014) (3)
- Steroids in prostate cancer: the jury is still out... and even more confused. (2015) (3)
- Genotype A1/A2 associated with neuroleptic malignant syndrome. (2005) (3)
- The antiproliferative effect of suramin on the cancer cell line SW-13 is mediated by the inhibition of transforming growth factor beta 1 (TGF-beta 1). (1992) (3)
- Molecular Cancer Therapeutics Association of Polymorphisms in AKT 1 and EGFR with Clinical Outcome and Toxicity in Non – Small Cell Lung Cancer Patients Treated with Gefitinib (2010) (3)
- Morphohistochemical characterization of suramin--induced chronic toxicity in rat kidney. (1992) (3)
- Biologic basis of ovarian metastasis of colorectal cancer. (2004) (3)
- Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation (2021) (2)
- Nicotine Metabolite Ratio in Smokers: A Real World Experience (2017) (2)
- The low opioid consumption in Italy depends on late palliative care (2013) (2)
- Fructose-1,6-diphosphate reduces acute ECG changes due to doxorubicin in isolated rat heart (1988) (2)
- Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: A study on circulating tumour DNA (2019) (2)
- Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs (2015) (2)
- Doxorubicin affects both the number and the morphology of specific atrial granules in dog heart. (1988) (2)
- Mitoxantrone, prednisone, pentostatin and bleomycin for patients with indolent non-Hodgkin's lymphoma relapsed or unresponsive to previous treatments. Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi (GISL) (2003) (2)
- Intravenous versus intrahepatic arterial 5-fluorouracil/leucovorin for treatment of colorectal cancer metastases. (2002) (2)
- Vascular Endothelial Growth Factor-A (VEGF-A) Single Nucleotide Polymorphisms and Endometriosis: Still a Controversial Issue: (2009) (2)
- Doxorubicin cardiotoxicity is reduced by pretreament with the iron chelator ADR-529 (1990) (2)
- Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3- deazaneplanocin A (DZNeP) with gemcitabine in pancreatic cancer cells (2012) (2)
- Changes of specific atrial granules induced by doxorubicin in dog's heart. (1990) (2)
- EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis (2012) (2)
- ResearchHypertension and hand-foot skin reactions related to VEGFR 2 genotype and improved clinical outcome following bevacizumab and sorafenib (2015) (2)
- Corticosteroids in oncology: use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. (2022) (2)
- Molecular mechanisms involved in the synergistic interaction of the EZH 2 inhibitor 3-deazaneplanocin A ( DZNeP ) with gemcitabine in pancreatic cancer cells (2012) (2)
- Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients. (2022) (2)
- Post-translational modifications and antioxidant properties of different therapeutic human serum albumins. (2021) (2)
- EPMA position paper in cancer: current overview and future perspectives (2015) (1)
- Predicting survival with artificial neural networks. (2003) (1)
- A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy (2014) (1)
- Comment on “High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma” (2015) (1)
- Abstract 4819: MicroRNA-21 (miR-21) in pancreatic ductal adenocarcinoma (PDAC): Correlation with clinical outcome and pharmacological aspects underlying its role in the modulation of gemcitabine activity (2010) (1)
- Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. (2011) (1)
- Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer. (2017) (1)
- Impact of locoregional approaches to liver metastases in patients with colorectal cancer. (2003) (1)
- Inhibitory Effect of Suramin and Heparin-Like Drugs on Experimental Angiogenesis (1993) (1)
- Pharmacogenetics in oncology (2008) (1)
- A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy (2014) (1)
- Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity. (2003) (1)
- [The physiopathological aspects of the atrial natriuretic factor]. (1992) (1)
- Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World (2018) (1)
- Pharmacogenetics and Personalized Medicine (2017) (1)
- Chronic administration of suramin induces neurotoxicity in rats (1997) (1)
- Cancer Therapy : Clinical Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide , Celecoxib , and Dexamethasone in Advanced Hormone-refractory Prostate Cancer (2009) (1)
- A phase I and pharmacokinetic study of irinotecan given as a 7 days continuous infusion in metastatic colorectal cancer patients pretreated with 5-FU or raltitrexed (2001) (1)
- Variously substituted (phosphonoacetamido)oxy analogues of geranylgeranyl diphosphate (GGdP) as GGdP-transferase (GGTase) inhibitors and antiproliferative agents. (2005) (1)
- The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies (2021) (1)
- [Recent pharmacotoxicologic and clinical findings on adriamycin]. (1985) (1)
- Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. (2013) (1)
- Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview. (2021) (1)
- Prognostic Value of CD133 Caused by Mutant K-Ras and B-Raf—Letter (2012) (1)
- Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC (2014) (1)
- Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management. (2022) (1)
- The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview (2016) (1)
- Results of a comprehensive pharmacogenetic analysis of dihydropyrimidine dehydrogenase in patients treated with fluoropyrimidines and patterns of polymorphisms partially related to treatment tolerability. (2012) (1)
- 1616PLIQUID BIOPSY TO MONITOR THE EVOLUTION OF NSCLC EGFR+DURING TREATMENT WITH GEFINTINIB. (2014) (1)
- the Modulation of Gemcitabine Activity Outcome and Pharmacologic Aspects Underlying Its Role in MicroRNA-21 in Pancreatic Cancer : Correlation with Clinical (2010) (1)
- Cardiac toxicity and antitumor activity of 4′-deoxy-4′-iodo-doxorubicinol (2008) (1)
- Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX. (2017) (1)
- Variations of circulating KRAS amount as a biomarker to monitor chemotherapy response in pancreatic cancer. (2017) (1)
- Expression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical response to CDK4/6 inhibitors in breast cancer. (2018) (1)
- Molecular mechanisms underlying the synergistic interaction of erlotinib , an epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor , with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells (2008) (1)
- [Preclinical pharmacology and clinical uses of topotecan]. (1999) (0)
- SP147 Pharmacogenomics in pancreatic cancer (2009) (0)
- Inhibition of acetylcholinesterase in patients receiving irinotecan (CPT-11) (2004) (0)
- Sequence E ffect o f I rinotecan a nd F luorouracil T reatment on P harmacokinetics a nd T oxicity i n C hemotherapy-Nai ve Metastatic C olorectal C ancer P atients (2001) (0)
- Epigenetics and breast cancer – prediction of drug activity (2008) (0)
- Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients (2010) (0)
- Circulating biomarkers of response to immunotherapy in cancer treatment. (2019) (0)
- Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens (2013) (0)
- MC13-0067 Association between Kras mutation in circulating cell-free tumor DNA and clinical progression of colorectal cancer in patients receiving cetuximab (2013) (0)
- Detection of BRAF and KRAS mutations in DNA released by tumors in peripheral blood by an advanced digital droplet PCR. (2013) (0)
- [Clinical efficacy of clofoctol in treating odontogenic infections]. (1986) (0)
- Association of eNOS polymorphisms with clinical outcome in bevacizumab-treated breast cancer patients. (2014) (0)
- A real-world application of liquid biopsy (LB) in metastatic colorectal cancer (mCRC). (2020) (0)
- [Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer.] (2021) (0)
- EGFR/KRAS-Germline mutation analyses in advanced non-small cell lung cancer (NSCLC) patients treated with Gefitinib/Erlotinib (2008) (0)
- Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia (2015) (0)
- A PRACTICAL APPROACH TO THERAPEUTIC DRUG MONITORING OF IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID ELEUKEMIA. THE TIKLET PROTOCOL. (2012) (0)
- EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. (2012) (0)
- Determination of Mitotane (DDD) and Principal Metabolite by a Simple HPLC-UV Method and Its Validation in Human Plasma Samples (2021) (0)
- Polycomb gene expression and single-nucleotide-polymorphisms (SNPS) in triple negative breast cancer (TNBC) patients. (2012) (0)
- 5-Fluorouracil exposure in adjuvant chemotherapy regimens is significantly related to disease free survival in colorectal cancer patients (2006) (0)
- Dihydropyrimidine dehydrogenase (DPD) deficiency: how to translate it in clinical practice? (2017) (0)
- Pleiotropic drug resistance in epithelial ovarian cancer (1991) (0)
- Genetic determinants in the study of colorectal cancer. (2004) (0)
- Cx. Incorporation of ctDNA analysis into routine follow-up for early detection of relapse may allow earlier initiation of alternate treatment modalities. Legal entity responsible for the study: The National Committee on Health Research (2019) (0)
- Suramin in metastatic colorectal cancer patients pretreated with fluoropyrimidine-based chemotherapy: a phase II trial (1995) (0)
- KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA. (2016) (0)
- Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes. (2019) (0)
- Effect of suramin on ethanol-induced gastric mucosal injury: Relationship between tissue distribution and severity of damage (1996) (0)
- Preclinical Development Molecular Mechanisms Involved in the Synergistic Interaction of the EZH 2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells (2012) (0)
- Correlation of expression of TK1 in plasma-derived exosomes with clinical response to CDK4/6 inhibitors in breast cancer. (2018) (0)
- 610 POSTER Synergistic cytotoxicity, inhibition of Akt and c-Kit phosphorylation and modulation of gene expression by sorafenib and gemcitabine in human pancreatic cancer cells (2006) (0)
- EPMA-World Congress 2015 (2016) (0)
- Induction of gemcitabine (GCB)-related genes by pemetrexed (MTA): Assessment of the best time interval between MTA and GCB administration (2007) (0)
- The emerging role of histone lysine demethylases in prostate cancer (2012) (0)
- Precision Medicine in Oncology: Glossary of Relevant Scientific Terms (2021) (0)
- 2162 : Synergistic Antitumor Activity of Zd6474, an Inhibitor of VEGFR and EGFR Signaling, With Gemcitabine and Ionizing Radiation Against Pancreatic Cancer (2006) (0)
- Lessons from the first ecancer symposium on angiogenesis in gastric cancer (2015) (0)
- The pharmacological bases of the antiangiogenic activity of paclitaxel (2013) (0)
- Pharmacogenetics of Angiogenesis (2010) (0)
- Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells Fast (2008) (0)
- Chapter 7 Molecular mechanisms involved in the synergistic interaction of the EZH 2 inhibitor 3-deazaneplanocin A ( DZNeP ) with gemcitabine in pancreatic cancer cells (2013) (0)
- Abstract C100: KRAS mutations in circulating cell-free DNA of colorectal cancer patients in progression after MoAb anti-EGFR therapy. (2013) (0)
- Antiproliferative effects and apoptosis induced by novel selective inhibitors of geranylgeranylation of cellular proteins (1997) (0)
- Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab (2014) (0)
- Targeting the upregulated PI3K-PDK1-Akt pathway: a drug discovery approach of treating cancer. (2012) (0)
- Phenylacetate inhibits protein prenylation in LNCaP cells transfected with the T24 H-ras gene (1995) (0)
- Capecitabine/Irinotecan Is Active and Well Tolerated in Patients with Advanced Colorectal Cancer (2001) (0)
- Cost-effectiveness of treatment optimisation with biomarkers for immunotherapy in solid tumours: a systematic review protocol (2021) (0)
- Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel (2021) (0)
- EZH2 Expression in Colorectal (CRC) Cancer: Single Nucleotide Polymorphism (SNP) Characterization and Correlation With Clinico-Pathological and Molecular Parameters (2012) (0)
- Comparison of ddPCR and sdPCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer. (2023) (0)
- C01*The detection of AR-V7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients (2016) (0)
- Low-toxic combination chemotherapy for limited small-cell lung cancer (1989) (0)
- Preparation and antiproliferative activity of phosphorus- and sulfur-containing geranylgeranyl derivatives (1997) (0)
- C11 Cytotoxic drugs (2011) (0)
- Irinotecan in 5-fluorouracil-refractory colorectal cancer. (2002) (0)
- The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs (2022) (0)
- Nanoscale engagement of immune checkpoint inhibitor PD-L1 in membrane lipid rafts (2022) (0)
- Determination of mitotane and principal metabolite by a simple HPLC-UV method and its validation in human plasma sample (2019) (0)
- H17Detection of secondary mutations associated with drug resistance in circulating tumor dna of patients with advanced ALK+ NSCLC (2015) (0)
- Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC. (2019) (0)
- Reply (2004) (0)
- Population pharmacokinetics and probability of target attainment of meropenem 1 in critically ill patients 2 3 (2019) (0)
- Embryonic stem cell pathways and chemotherapy response: an unexplored route. (2013) (0)
- [Effect of amrinone on the cardiotoxicity induced by adriamycin in the rat]. (1985) (0)
- Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer (2017) (0)
- Selective induction of PD-L1 expression in plasma-derived exosomes by gem-nab-paclitaxel vs. folfirinox in pancreas cancer. (2018) (0)
- PHARMACOGENETIC EVALUATION OF AURORA A KINASE IN COLORECTAL CANCERS (2007) (0)
- E07DPYD c.1905 + 1G > A and c.2846A > T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer (2015) (0)
- 1932MO Ki67 expression and CDK4/6i activity: An emerging role for PIK3CA mutations in metastatic breast cancer patients (2020) (0)
- Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region (2020) (0)
- Prevention of Capecitabine Toxicity Using a 5-FU Test Dose (2018) (0)
- PLASMA/SALIVA AND GENOTYPIC/PHENOTYPIC DIFFERENCES OF NICOTINE METABOLITE RATIO. (2018) (0)
- Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival. (2022) (0)
- A polymorphism in a transporter of testosterone as a determinant of androgen independence in prostate cancer (2008) (0)
- Deposited in DRO : 12 June 2012 Version of attached le : Published Version Peer-review status of attached le : Peer-reviewed Citation for published item : (2014) (0)
- Synergistic chemotherapeutic activity of gemcitabine and fluvastatin on pancreas cancer in vitro (2001) (0)
- Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer. (2011) (0)
- LASER MICRODISSECTION (LMD) AND PRIMARY CELL CULTURES IMPROVE PHARMACOGENETIC ANALYSIS IN PANCREATIC ADENOCARCINOMA ALLOWING THE USE OF GENE EXPRESSION LEVELS AND WHO GRADING AS PROGNOSTIC MARKERS (2008) (0)
- May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients? (2019) (0)
- Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy (2017) (0)
- Evaluation of EZH2 SNPs in cholangiocarcinoma patients. (2012) (0)
- V79/AP4 cell growth is suppressed by drugs which inhibit bfGf-mitogenic activity and by antisense oligonucleotides to bFGF (1992) (0)
- Impact of IVS14+1G>A and 2846A>T DPYD polymorphisms on toxicity outcome of patients treated with fluoropyrimidine-containing regimens. (2013) (0)
- Association of PD-L1 mRNA levels in plasma-derived exosomes with response to nivolumab and pembrolizumab in melanoma and NSCLC. (2018) (0)
- Characteristics of smokers according to their Nicotine Metabolite Ratio, preliminary results from a real-life experience (2017) (0)
- A novel multi-target pyrazolopyrimidine derivative with anti-neoplastic properties, CLM29, is active against medullary thyroid cancer in vitro and in vivo (2013) (0)
- Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation. Final report (2007) (0)
- OP62 Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib (2009) (0)
- Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients (2016) (0)
- Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed in bladder transitional cell cancer (2006) (0)
- Listening understanding and acting (lung): focus on communicational issue in thoracic oncology (2019) (0)
- Functional characterization of EZH2 single nucleotide polymorphism and correlation of EZH2 expression with clinico-pathological and molecular parameters in colorectal (CRC) cancer samples. (2012) (0)
- Ceramide Analogues as a New Strategy for Anticancer Drug Development (2000) (0)
- New geranylgeranylderivate, process for their preparation and related pharmaceutical compositions (1996) (0)
- Resistance to biologic drugs (2014) (0)
- Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma (2022) (0)
- Simultaneous, but not consecutive combination with folinate salts potentiates 5-fluorouracil antitumor activity in vitro (2017) (0)
- PP069 Health Technology Assessment Of Radium-223 Dichloride In Resistant Metastatic Prostate Cancer (2017) (0)
- MYCOPHENOLATE MOPHETIL AND PANCREAS TRANSPLANT ALO (2005) (0)
- AN EZH2 POLYMORPHISMS IS ASSOCIATED WITH CLINICAL OUTCOME IN METASTATIC COLORECTAL CANCER PATIENTS. (2012) (0)
- [Possible role of adriamycinol in the cardiotoxicity induced by adriamycin in the rat]. (1985) (0)
- Genetic analysis of cytidine deaminase (CDA) for the prediction of response to chemotherapy and survival in advanced non-small-cell lung cancer (NSCLC) patients treated with gemcitabine (2006) (0)
- Case Study of the Month Durable Complete Response to Frontline Docetaxel in an Advanced Prostate Cancer Patient with Favourable CYP 1 B 1 Isoforms : Suggestion for Changing Paradigms ? (2008) (0)
- The Role of Adjuvant Therapy After Liver Resection for Colorectal Metastases. (2001) (0)
- Abstract P1-08-31: Putative role of genetic variants of eNOS in survival and toxicity of patients given antiangiogenic therapy (2013) (0)
- Doxorubicin dose-dependently widens the SαT segment of the ECG the isolated rat heart segment of the ECG in th isolated rat heart (1989) (0)
- TISSUE PENETRATIONS AND EFFICACY OF CEFPODOXIME PROXETIL IN THE TREATMENT OF ODONTOGENIC INFECTIONS (1993) (0)
- Rebuttal letter: Different underlying mechanism might explain the absence of a significant difference in AUC of linezolid for different ABCB1 genotypes. (2019) (0)
- Lung tissue penetration and plasma pharmacokinetics of azithromycin after multiple oral doses of 500 and 1000 mg in adults (2001) (0)
- EZH 2 polymorphism and benefit from bevacizumab in colorectal cancer : another piece to the puzzle (2012) (0)
- The heparan sulfate HHS-5 inhibits corneal angiogenesis induced by chemical cauterization in rats ☆ (1992) (0)
- Pharmacogenetics of Antiangiogenic Therapy (2008) (0)
- CYTOTOXIC ACTIVITY OF INHIBITORS OF ARACHIDONIC ACID METABOLISM IN HUMAN PANCREATIC CANCER CELLS IN VITRO (2000) (0)
- Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients (2015) (0)
- The rs 2071559 AA VEGFR-2 Genotype Frequency Is Significantly Lower in Neovascular Age-RelatedMacular Degeneration Patients (2014) (0)
- 3067 POSTER Irinotecan Metronomic Chemotherapy (MC) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation (2007) (0)
- Genes involved in gemcitabine activity: pancreas cancer vs primary cell cultures (2006) (0)
- Abstract P5-17-06: The deficient eNOS c.894G>T genotype is not associated with increased severity of hypertension and proteinuria in breast cancer patients receiving bevacizumab (2012) (0)
- Embryonic stem cell pathways and chemotherapy response: an unexplored route. (2013) (0)
- MICRORNA-21 FROM BENCH TO BEDSIDE AND BACK: A POTENTIAL MARKER OF CLINICAL OUTCOME AND A TARGET TO OVERCOME RESISTANCE TO GEMCITABINE IN PANCREATIC CANCER (2010) (0)
- Abstract 4375: Sunitinib alone and in combination with SN-38 is active against anaplastic thyroid cancer (2012) (0)
- AbstractAzidothymidine (AZT), 5-fluorouracil (5-FU) and l-folinic acid (FA): A pilot study in metastatic colorectal cancer (MCRC) (1994) (0)
- The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response (2018) (0)
- Selective induction of PD-L1 expression in plasma-derived exosomes by gemcitabine-nab-paclitaxel vs. FOLFIRINOX in pancreas cancer. (2018) (0)
- Effects of suramin on V79-AP4 fibroblast cell line (1990) (0)
- TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients. (2023) (0)
- Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment (2017) (0)
- 242: Pharmacogenetics Determinants of Anticancer Activity of Intravescical Gemcitabine in Patients with Superficial Transitional Cell Carcinoma (TCC) of The Bladder (2007) (0)
- KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC: an analysis on circulating tumor DNA (2015) (0)
- Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: Independent actors or reciprocal drivers? A translational study by Meet-Uro group. (2018) (0)
- THE OFFICIAL JOURNAL OF SOCIETÀ ITALIANA DI FARMACOLOGIA (2022) (0)
- Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years (2023) (0)
- 12 Pharmacogenetics of drug transporters (2010) (0)
- Doxorubicin cardiotoxicity in the dog: A morphofunctional study (1988) (0)
- Plasma pharmacokinetics of cinmetacin following oral administration in healthy volunteers. (1988) (0)
- Analysis of the androgen receptor status in liquid biopsy to predict the outcome to abiraterone and enzalutamide in CRPC patients (2019) (0)
- Clinical and genetic characterization of dihydropyrimidine dehydrogenase (DPD) deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele (2011) (0)
- EP-0997: Polymorphisms of Akt and EZH2 as predict factor of radiochemotherapy in patients with glioblastoma (GBM) (2013) (0)
- ICRF-187 prevents ECG alterations induced by doxorubicin treatment in the rat (1990) (0)
- Exploratory analysis of circulating pro- and antiangiogenic factors in metastatic colorectal cancer (mCRC) patients, treated with GONO-FOLFOXIRI plus bevacizumab (BV). (2010) (0)
- Pharmacogenetics to predict adverse drug reactions in oncology: distant goal or reality? (2015) (0)
- Corrigendum to "Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors" [Cancer Treatm. Rev. 74 (2019) 21-28]. (2019) (0)
- DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients (2019) (0)
- Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer (2015) (0)
- Single nucleotide polymorphisms and clinical outcome in biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine (2008) (0)
- The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report (2019) (0)
- PP 92 Clinical and genetic characterization of dihydropyrimidine dehydrogenase deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele (2011) (0)
- The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience (2016) (0)
- Doxorubicin modifies plasma levels of immunoreactive atrial natriuretic factor (1990) (0)
- Genome Wide Association Studies (GWAS) (2018) (0)
- Radiosensitizing potential of small organic molecules toward hypoxic tumor cells in the radiotherapy (2008) (0)
- Expression of gemcitabine and cisplatin-related genes according to histology and stage in non-small-cell lung cancer (NSCLC) (2008) (0)
- Stable analogues of geranylgeranyl diphosphate possessing a (Z,E,E)-geranylgeranyl side-chain as inhibitors of prenyl protein transferases (2005) (0)
- Author's reply: To PMID 22443211. (2013) (0)
- PO-0630: The role of mc4r gene polymorphisms in gbm patients treated with concomitant radio-chemotherapy (2017) (0)
- Small Cell Lung Cancer Patients − Advanced Non Treated − Response and Survival in Gemcitabine / Cisplatin Polymorphisms with XPD , and CDA , ERCC 1 Correlation of (2008) (0)
- Taxol inhibits protein isoprenylation in PC-3 prostate cancer cells (1995) (0)
- Vascular Endothelial Growth Factor-A (VEGF-A) Single Nucleotide Polymorphisms and Endometriosis: Still a Controversial Issue (2009) (0)
- Pathophysiology and pharmacological targets of diabetic macular edema : an 1 updated review (2014) (0)
- In vitro schedule-dependent interaction and gene expression modulation by gemcitabine and pemetrexed in non-small cell lung cancer (NSCLC) cell lines. (2004) (0)
- 228PPATTERN OF DIHYDROPYRIMIDINE DEHYDROGENASE GENETIC VARIANTS IN PATIENTS WITH VARIOUS DEGREES OF TOLERABILITY OF FLUOROPYRIMIDINE TREATMENT. (2014) (0)
- Cytotoxic Drugs (2019) (0)
- Control of cell growth by ceramide analogues: a new strategy for anticancer drug development (1999) (0)
- Immune Checkpoint Inhibitors and Cardiotoxicity: Reverse Translational Research by Using Real World Safety Data from the European Spontaneous Reporting System (2021) (0)
- A NEW HPLC-UV METHOD COMPARED WITH HPLC-MS FOR DAPTOMYCIN LEVELS IN HUMAN PLASMA SAMPLES (2020) (0)
- Advances in Brief MCF-10 A Cells Infected with the int-20 ncogene Induce Angiogenesis in the Chick Chorioallantoic Membrane and in the Rat Mesentery 1 (2007) (0)
- SAFETY MATTERS: THE TROUBLED AND FINALLY SUCCESSFUL STORY OF DIHYDROPYRIMIDINE DEHYDROGENASE PHARMACOGENETIC TEST IN CANCER PATIENTS (2021) (0)
- D3-06: Correlation of cytidine deaminase and DNA repair genes polymorphisms with response and survival in gemcitabine/cisplatin treated advanced non-small-cell lung cancer patients (2007) (0)
- Importance of preclinical investigations of the integration of capecitabine into polychemotherapy regimens. (2005) (0)
- CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients (2023) (0)
- Effect of fluvastatin on colon tumor cells (1996) (0)
- Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib (2022) (0)
- Breast lymphomas around breast implants. (2014) (0)
- Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab (2014) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Romano Danesi?
Romano Danesi is affiliated with the following schools:
